Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes

What Was Tested

Researchers studied Insulin Aspart in this randomized controlled trial publication.

Who Took Part

The abstract describes 748 patients taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

After a 4-week run-in period, patients were randomized 1 : 1 to 16 weeks of treatment.

A total of 748 patients were screened, 664 were exposed to trial drug and 604 completed the trial.

How the Study Was Run

The researchers set it up as a randomized, open-label, multicenter and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.

Nothing was hidden in this open-label Insulin Aspart study: the patients and staff both knew the treatment.

More than one site took part, so the patients came from several places.

Groups ran in parallel: each of the patients stayed in one arm throughout.

The timeline in the abstract includes 4 weeks.

This was a multicentre, open-label, parallel group trial.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hypoglycemia, Hypoglycemic Agents, Insulin and Insulin Aspart.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Insulin Aspart in 748 patients over 4 weeks.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Aspart compound page.